Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
QSI Transcript
Quantum-Si incorporated (QSI) Q4 2025 Earnings Call Transcript
Positive3-4
The earnings call summary indicates positive developments such as successful prototype milestones, new product launches, and a strong financial position. The Q&A section reveals consistent consumable sales and strategic planning for the Proteus launch, despite some uncertainties in customer acquisition models and NIH funding. Overall, the company's strategic focus on product development and a strong balance sheet suggest a positive outlook, likely leading to a stock price increase.
Quantum-Si incorporated (QSI) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call presents mixed signals: revenue has decreased, and there are uncertainties in NIH funding, but there is optimism about product launches and market opportunities. The Q&A reveals management's evasiveness on key issues, adding uncertainty. Despite financial constraints, cost controls are evident. Strong financial metrics are offset by weak guidance and lack of clarity, leading to a neutral sentiment.
Quantum-Si incorporated (QSI) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call summary and Q&A reveal strong financial performance with an 84% revenue increase and a 58% gross margin. Management is optimistic about growth, especially in Q4, and is implementing flexible sales models to overcome capital constraints. The company is focused on innovation and market expansion, particularly in pharma and biotech. Despite some unclear responses, the overall sentiment is positive, supported by strategic product launches and a solid cash position. The stock price is likely to experience a positive movement in the next two weeks.
Quantum-Si incorporated (NASDAQ:QSI) Q1 2025 Earnings Call Transcript
Unknown5-17
The earnings call reveals mixed signals: strong revenue growth and international expansion are positive, but uncertainties in NIH funding and a slowdown in the U.S. academic market are concerning. The Q&A session highlights confidence in the biopharma market and positive feedback on product launches, but unclear responses on tariffs and a dip in dividend income raise caution. With a robust cash position and strategic partnerships, the short-term stock reaction is likely neutral, balancing positive growth against market uncertainties.
QSI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
